24463-41-0

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Methyl-4-oxo-cyclohexanecarboxylic acid is utilized as a key intermediate in the production of various pharmaceuticals. Its unique structure allows for the creation of diverse drug molecules, contributing to the development of new treatments for a range of medical conditions.
Used in Agrochemical Production:
In the agrochemical industry, 1-Methyl-4-oxo-cyclohexanecarboxylic acid serves as an essential building block for the synthesis of compounds used in crop protection and pest management. Its incorporation into these products can enhance their effectiveness and selectivity.
Used in Organic Chemistry Research:
1-Methyl-4-oxo-cyclohexanecarboxylic acid is employed as a valuable component in organic chemistry research, where its properties are explored for the development of novel chemical reactions and the synthesis of complex organic molecules.
Used in Drug Discovery:
Due to its potential pharmacological properties, including anti-inflammatory and analgesic effects, 1-Methyl-4-oxo-cyclohexanecarboxylic acid is used in drug discovery research. It is studied for its capacity to contribute to the creation of new therapeutic agents that could address unmet medical needs.
Each application underscores the compound's multifaceted role in different industries, highlighting its significance in chemical synthesis and therapeutic development.

Upstream product

• 37480-41-4 methyl 1-methyl-4-oxo-1-cyclohexanecarboxylate 
• 27036-60-8 4-[1,3]dioxolan-2-yl-4-methyl-cyclohexanol 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 24730-88-9 ethyl 8-methyl-1,4-dioxa-spiro[4.5]decane-8-carboxylate 
• 412293-42-6 8-methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 147905-77-9 ethyl 1-methyl-4-oxo-1-cyclohexanecarboxylate 
• 37480-31-2 4-methoxy-1-methyl-cyclohex-3-enecarboxylic acid methyl ester 

Downstream Products

• 37480-41-4 methyl 1-methyl-4-oxo-1-cyclohexanecarboxylate 
• 5202-56-2 1-methyl-4-methylenecyclohexanecarboxylic acid 
• 1134198-11-0 benzyl 1-methyl-4-oxo-cyclohexanecarboxylate 
• 69082-04-8 4-(4-methoxy-phenyl)-1-methyl-cyclohexanecarboxylic acid 
• 61414-84-4 4-(4-methoxy-phenyl)-1-methyl-cyclohex-3-enecarboxylic acid 
• 148839-92-3 1-(4-methoxy-phenyl)-4-methyl-2-oxa-bicyclo[2.2.2]octan-3-one 

Relevant academic research and scientific papers

4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof

Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation

Our initial structure-activity relationship studies on 7-methoxy-4-morpholino-benzothiazole derivatives featured by aryloxy-2-methylpropanamide moieties at the 2-position led to identification of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties. However, poor intrinsic solubility and low to moderate oral bioavailability made this series unsuitable for further development. Further optimization using structure-based drug design approach resulted in discovery of potent and selective adenosine A2A receptor antagonists bearing substituted 1-methylcyclohexyl-carboxamide groups at position 2 of the benzothiazole scaffold and endowed with better solubility and oral bioavailability. Compounds 41 and 49 demonstrated a number of positive attributes with respect to in vitro ADME properties. Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat. Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.

2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS

The invention relates to novel tetrahydro-lH-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.